
According to Benzinga Pro data Ironwood Pharmaceuticals (NASDAQ:IRWD) posted a 25.91% decrease in earnings from Q3. Sales, however, increased by 12.9% over the previous quarter to $117.13 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Ironwood Pharmaceuticals is not utilizing their capital as effectively as possible. In Q3, Ironwood Pharmaceuticals earned $55.84 million and total sales reached $103.75 million.